StockNews.AI
IOVA
StockNews.AI
98 days

IOVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Iovance Stockholders and Encourages Investors to Contact the Firm

1. Iovance is under investigation for potential securities law violations. 2. First quarter 2025 revenue dropped to $49.3 million from $73.7 million. 3. Full-year revenue guidance was cut from $450 million-$475 million to $250 million-$300 million. 4. Stock price fell significantly on heavy trading volume following the news. 5. Legal actions may impact investor confidence and stock performance.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The sharp revenue decrease and investigation will likely deter investors, reminiscent of past scenarios like Valeant Pharmaceuticals, which faced aggressive scrutiny post-revenue reporting, leading to a substantial stock crash.

How important is it?

The article highlights significant revenue declines and legal challenges, crucial to investors and potential affects on IOVA's stock trajectory.

Why Short Term?

Immediate investor sentiment will be influenced by current investigations and revenue cuts, signaling short-term repercussions similar to other firms that faced legal scrutiny swiftly affecting stock prices.

Related Companies

VRTXKITE
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ:IOVA) on behalf of Iovance stockholders. Our investigation concerns whether Iovance has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 8, 2025, Iovance released its first quarter 2025 financial results, revealing a quarterly total product revenue of $49.3 million, a significant decline from the prior quarter's $73.7 million. Iovance also announced its full fiscal year 2025 total product revenue guidance had been slashed from $450 million - $475 million to $250 million - $300 million, a reduction of over 40% at the midpoint. The Company stated it was "revising full-year 2025 revenue guidance to reflect recent launch dynamics" of the Company's T cell immunotherapy, Amtagvi® (lifileucel). Amtagvi was commercially launched in the U.S. in the first half of 2024. Following this news, Iovance stock dropped on unusually heavy trading volume. If you purchased or otherwise acquired Iovance shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News